Portal de Periódicos da CAPES

Celecoxib for Treatment of Nocturia Caused by Benign Prostatic Hyperplasia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

2008; Elsevier BV; Volume: 72; Issue: 4 Linguagem: Inglês

10.1016/j.urology.2008.04.069

1527-9995

Siavash Falahatkar, Gholamreza Mokhtari, Farshid Pourreza, Seyed Alaeddin Asgari, Alireza Noshad Kamran,

Hormonal and reproductive studies

Objectives Nocturia is a well-recognized symptom of benign prostatic hyperplasia (BPH), which is commonly treated by α1-blockers and/or 5α-reductase inhibitors. However, the effectiveness of these drugs for nocturia has been reported to be only 25%-39%. The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase-2 inhibitor, in the treatment of patients with BPH complaining of nocturia. Methods This was a prospective, randomized, double-blind, placebo-controlled study. A total of 80 men with lower urinary tract symptoms and BPH were entered into the study and were randomized to receive celecoxib, 100 mg at 9 pm vs placebo for 1 month. The inclusion criteria also included a total International Prostate Symptom Score >8 and complaints of ≥2 voids nightly. The efficacy and safety of the treatment were assessed by changes in the urinary flow and symptoms between baseline and 1 month of follow-up. Results In the celecoxib group (n = 40), the mean nocturnal frequency (±SD) decreased from 5.17 ± 2.1 to 2.5 ± 1.9 (P < .0001), and the mean International Prostate Symptom Score (±SD) decreased from 18.2 ± 3.4 to 15.5 ± 4.2 (P < .0001). In the control group (n = 40), the mean nocturnal frequency (±SD) decreased from 5.30 ± 2.4 to 5.12 ± 1.9 (P > .05), and the mean International Prostate Symptom Score (±SD) decreased from 18.4 ± 3.1 to 18 ± 3.9 (P > .05). A statistically significant difference was found between the 2 groups (P < .0001). No statistically significant differences were found in the changes in the peak flow rate between the celecoxib and control groups or in celecoxib group between baseline and 1 month (P > .05). No significant side effects were reported. Conclusions Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia. Our results suggest a novel treatment option for this common condition. Nocturia is a well-recognized symptom of benign prostatic hyperplasia (BPH), which is commonly treated by α1-blockers and/or 5α-reductase inhibitors. However, the effectiveness of these drugs for nocturia has been reported to be only 25%-39%. The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase-2 inhibitor, in the treatment of patients with BPH complaining of nocturia. This was a prospective, randomized, double-blind, placebo-controlled study. A total of 80 men with lower urinary tract symptoms and BPH were entered into the study and were randomized to receive celecoxib, 100 mg at 9 pm vs placebo for 1 month. The inclusion criteria also included a total International Prostate Symptom Score >8 and complaints of ≥2 voids nightly. The efficacy and safety of the treatment were assessed by changes in the urinary flow and symptoms between baseline and 1 month of follow-up. In the celecoxib group (n = 40), the mean nocturnal frequency (±SD) decreased from 5.17 ± 2.1 to 2.5 ± 1.9 (P < .0001), and the mean International Prostate Symptom Score (±SD) decreased from 18.2 ± 3.4 to 15.5 ± 4.2 (P < .0001). In the control group (n = 40), the mean nocturnal frequency (±SD) decreased from 5.30 ± 2.4 to 5.12 ± 1.9 (P > .05), and the mean International Prostate Symptom Score (±SD) decreased from 18.4 ± 3.1 to 18 ± 3.9 (P > .05). A statistically significant difference was found between the 2 groups (P < .0001). No statistically significant differences were found in the changes in the peak flow rate between the celecoxib and control groups or in celecoxib group between baseline and 1 month (P > .05). No significant side effects were reported. Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia. Our results suggest a novel treatment option for this common condition.